MedTrace Logo

Safety and Efficacy Study of CF101 to Treat Psoriasis

NCT00428974 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2023-02-08

Study results available
· View outcomes & findings →

Summary

This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated every 12 hours (q12h) with CF101 capsules, or placebo capsules, for 12 weeks. The safety of treatment will be carefully assessed through clinical and laboratory monitoring. The effect of treatment on psoriasis will be evaluated through standard techniques of examination and measurement of the severity of skin involvement.

Conditions

Interventions

DRUG

CF101 1mg

CF101 1 mg q12 hours for 12 weeks

DRUG

CF101 2mg

CF101 2 mg q12 hours for 12 weeks

DRUG

CF101 4mg

CF101 4 mg q12 hours for 12 weeks

DRUG

Placebo

Placebo tablets q12 hours for 12 weeks

Sponsors & Collaborators

  • Can-Fite BioPharma

    lead INDUSTRY

Principal Investigators

  • Michael David, MD · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00428974 on ClinicalTrials.gov